Chronic Gout Clinical Trial
Official title:
A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks With Co-Administration of Weekly Doses of Methotrexate in Patients With Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)
This trial is to assess efficacy, safety, blood levels and bodily effects of up to 2 dose levels of intravenous (IV) pegloticase (KRYSTEXXA) infusions at every 4 week intervals (Q4 Weeks) for up to 6 months (Day 1 to 24 weeks with an optional 24 - 48 weeks treatment duration) when given in combination with weekly oral doses of methotrexate (MTX). The goal is to identify an appropriate dose to be administered every 4 weeks to be used for future clinical trials for patients with chronic gout that does not adequately respond to conventional therapy.
The primary objective is to choose a dose for further investigation by assessing the effect of up to 2 dose levels of pegloticase administered IV Q4 weeks, co-administered with weekly doses of oral MTX, as measured by the sustained normalization of serum uric acid (sUA) to < 6 mg/dL for at least 80% of the time during Month 6 and the duration of sUA to < 6 mg/dL over 24 week treatment period in adult participants with chronic gout refractory to conventional therapy. Acquired from Horizon in 2024. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04596540 -
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
|
Phase 3 | |
Completed |
NCT02956278 -
The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics
|
Phase 4 | |
Completed |
NCT03905512 -
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
|
Phase 2 | |
Recruiting |
NCT05312268 -
Rasburicase Treatment in Chronic Gouty Arthritis
|
Phase 4 | |
Completed |
NCT04513366 -
A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
|
Phase 3 |